Sessions are scheduled in local time (CEST)

Browsing Over 485 Presentations

Sort By
AiCME - Targeted adjuvant strategies for HR-positive HER2-negative early breast cancer: Who can benefit, and how can we optimize their use?

Welcome and introductions (ID 498)

Lecture Time
11:30 - 12:30
Session Name
AiCME - Targeted adjuvant strategies for HR-positive HER2-negative early breast cancer: Who can benefit, and how can we optimize their use?
Room
Hamburg Hall
Date
Thu, 11.05.2023
Time
11:30 - 12:30
Speakers
  • All Speakers (na, Switzerland)
Authors
  • All Speakers (na, Switzerland)
AiCME - Targeted adjuvant strategies for HR-positive HER2-negative early breast cancer: Who can benefit, and how can we optimize their use?

Assessing risk of recurrence in HR-positive, HER2-negative early breast cancer (ID 499)

Lecture Time
12:30 - 12:30
Session Name
AiCME - Targeted adjuvant strategies for HR-positive HER2-negative early breast cancer: Who can benefit, and how can we optimize their use?
Room
Hamburg Hall
Date
Thu, 11.05.2023
Time
11:30 - 12:30
Speakers
  • All Speakers (na, Switzerland)
Authors
  • All Speakers (na, Switzerland)
AiCME - Targeted adjuvant strategies for HR-positive HER2-negative early breast cancer: Who can benefit, and how can we optimize their use?

Impact of oral targeted adjuvant therapies in patients with HR-positive, HER2-negative early breast cancer (ID 500)

Lecture Time
12:30 - 12:30
Session Name
AiCME - Targeted adjuvant strategies for HR-positive HER2-negative early breast cancer: Who can benefit, and how can we optimize their use?
Room
Hamburg Hall
Date
Thu, 11.05.2023
Time
11:30 - 12:30
Speakers
  • All Speakers (na, Switzerland)
Authors
  • All Speakers (na, Switzerland)
AiCME - Targeted adjuvant strategies for HR-positive HER2-negative early breast cancer: Who can benefit, and how can we optimize their use?

Optimizing adherence and persistence with oral targeted adjuvant therapies in HR-positive, HER2-negative early breast cancer (ID 501)

Lecture Time
12:30 - 12:30
Session Name
AiCME - Targeted adjuvant strategies for HR-positive HER2-negative early breast cancer: Who can benefit, and how can we optimize their use?
Room
Hamburg Hall
Date
Thu, 11.05.2023
Time
11:30 - 12:30
Speakers
  • All Speakers (na, Switzerland)
Authors
  • All Speakers (na, Switzerland)
AiCME - Targeted adjuvant strategies for HR-positive HER2-negative early breast cancer: Who can benefit, and how can we optimize their use?

Shared decision-making in HR-positive, HER2-negative early breast cancer: Enhancing patient-provider communication (ID 502)

Lecture Time
12:30 - 12:30
Session Name
AiCME - Targeted adjuvant strategies for HR-positive HER2-negative early breast cancer: Who can benefit, and how can we optimize their use?
Room
Hamburg Hall
Date
Thu, 11.05.2023
Time
11:30 - 12:30
Speakers
  • All Speakers (na, Switzerland)
Authors
  • All Speakers (na, Switzerland)
AiCME - Targeted adjuvant strategies for HR-positive HER2-negative early breast cancer: Who can benefit, and how can we optimize their use?

Questions and take-home messages (ID 503)

Lecture Time
12:30 - 12:30
Session Name
AiCME - Targeted adjuvant strategies for HR-positive HER2-negative early breast cancer: Who can benefit, and how can we optimize their use?
Room
Hamburg Hall
Date
Thu, 11.05.2023
Time
11:30 - 12:30
Speakers
  • All Speakers (na, Switzerland)
Authors
  • All Speakers (na, Switzerland)
AstraZeneca - HR+ metastatic breast cancer – how do we stay ahead of a dynamic disease?

Introduction (ID 66)

Lecture Time
11:30 - 11:35
Session Name
AstraZeneca - HR+ metastatic breast cancer – how do we stay ahead of a dynamic disease?
Room
Munich Hall
Date
Thu, 11.05.2023
Time
11:30 - 12:30
Speakers
  • Javier Cortes (Madrid and Barcelona, Spain)
Authors
  • Javier Cortes (Madrid and Barcelona, Spain)
AstraZeneca - HR+ metastatic breast cancer – how do we stay ahead of a dynamic disease?

Reacting to a dynamic disease (ID 67)

Lecture Time
11:35 - 11:45
Session Name
AstraZeneca - HR+ metastatic breast cancer – how do we stay ahead of a dynamic disease?
Room
Munich Hall
Date
Thu, 11.05.2023
Time
11:30 - 12:30
Speakers
  • Komal Jhaveri (New York, NY, United States of America)
Authors
  • Komal Jhaveri (New York, NY, United States of America)
AstraZeneca - HR+ metastatic breast cancer – how do we stay ahead of a dynamic disease?

Moving ahead of a dynamic disease (ID 68)

Lecture Time
11:45 - 11:55
Session Name
AstraZeneca - HR+ metastatic breast cancer – how do we stay ahead of a dynamic disease?
Room
Munich Hall
Date
Thu, 11.05.2023
Time
11:30 - 12:30
Speakers
  • François Clément Bidard (Paris, CE, France)
Authors
  • François Clément Bidard (Paris, CE, France)
AstraZeneca - HR+ metastatic breast cancer – how do we stay ahead of a dynamic disease?

Gaining momentum with new modalities (ID 69)

Lecture Time
11:55 - 12:05
Session Name
AstraZeneca - HR+ metastatic breast cancer – how do we stay ahead of a dynamic disease?
Room
Munich Hall
Date
Thu, 11.05.2023
Time
11:30 - 12:30
Speakers
  • Javier Cortes (Madrid and Barcelona, Spain)
Authors
  • Javier Cortes (Madrid and Barcelona, Spain)
AstraZeneca - HR+ metastatic breast cancer – how do we stay ahead of a dynamic disease?

Q&A / discussion (ID 70)

Lecture Time
12:05 - 12:30
Session Name
AstraZeneca - HR+ metastatic breast cancer – how do we stay ahead of a dynamic disease?
Room
Munich Hall
Date
Thu, 11.05.2023
Time
11:30 - 12:30
Speakers
  • To be Announced (Barcelona, Spain)
Authors
  • To be Announced (Barcelona, Spain)
Beyond breast cancer: Survivorship

Cope with the transition: Setting up a post-cancer consultation (ID 160)

Lecture Time
08:45 - 09:05
Session Name
Beyond breast cancer: Survivorship
Room
Frankfurt Hall
Date
Sat, 13.05.2023
Time
08:45 - 10:15
Speakers
  • Patricia Ganz (Los Angeles, CA, United States of America)
Authors
  • Patricia Ganz (Los Angeles, CA, United States of America)